Skip to content
Homepage
Author:
Wuxi Biologics
Posted Date:
September 24, 2026
WuXi Biologics Passes Another FDA GMP Inspection, Reinforcing Its Quality Track Record and Commercial Supply Reliability
Wuxi Biologics
September 24, 2026
WuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadership
Wuxi Biologics
September 16, 2026
WuXi Biologics Reports Strong Profitable Growth in H1 2026
Wuxi Biologics
August 25, 2026
WuXi Biologics Recognized for Industry Top Sustainable Biopharma Practices Empowering the Industry’s Transformation Through Green CRDMO
Wuxi Biologics
August 18, 2026
WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMO
Wuxi Biologics
July 28, 2026
WuXi Biologics Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year
Wuxi Biologics
July 8, 2026
WuXi Biologics’ Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
Wuxi Biologics
June 18, 2026
